Supplementary Documents [IFRS]

Financial results for the first three months of the fiscal year 2020 (FY2020)

Astellas Pharma Inc.

- Q1/FY2020 Financial Results
- Pipeline list

Cautionary Notes

In this material, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management's current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas' intellectual property rights by third parties.

Information about pharmaceutical products (including products currently in development) which is included in this material is not intended to constitute an advertisement or medical advice.

1. Consolidated Results (Full Basis)

Unit: B¥

	FY19 APR. - JUN.	FY20 APR. - JUN.	Change	Change (%)	FY19 Full Year	Initial Forecasts FY20 Full Year	Revised Forecasts FY20 Full Year	Change from FY19 FY20 Change (%)
Revenue	334.1	307.0	-27.2	-8.1%	1,300.8	1,282.0	1,256.5	-3.4%
Cost of sales	70.5	59.7	-10.9	-15.4%	276.7			
Ratio to Revenue	21.1%	19.4%			21.3%			
Gross profit	263.6	247.3	-16.3	-6.2%	1,024.1			
SG&A expenses	117.5	120.8	3.3	2.8%	499.3			
Ratio to Revenue	35.2%	39.3%			38.4%			
Advertising and Sales Promotion	41.3	42.0	0.7	1.8%	172.4			
Personnel expenses	43.6	45.7	2.1	4.8%	179.8			
Other	32.6	33.1	0.5	1.5%	147.0			
R&D expenses	53.5	57.3	3.8	7.1%	224.2	239.0	233.5	4.1%
Ratio to Revenue	16.0%	18.7%			17.2%	18.6%	18.6%	
Amortisation of intangible assets	7.2	5.9	-1.3	-18.4%	21.2			
Share of profit (loss) of investments accounted for using equity method	-0.7	-0.0	0.7	-	-1.7			
Other income	4.5	2.2	-2.3	-50.4%	12.2			
Net foreign exchange gains	0.5	1.1	0.7	131.6%	-			
Other expenses	12.2	4.8	-7.4	-60.6%	45.9			
Impairment losses	-	3.3	3.3	-	13.8			
Fair value remeasurements on contingent consideration	11.4	0.2	-11.2	-98.5%	11.2			
Operating profit	77.1	60.8	-16.3	-21.1%	244.0	252.0	246.5	1.0%
Ratio to Revenue	23.1%	19.8%			18.8%	19.7%	19.6%	
Finance income	0.8	0.4	-0.4	-50.5%	4.4			
Finance expenses	1.3	1.0	-0.4	-27.8%	3.0			
Profit before tax	76.5	60.2	-16.3	-21.3%	245.4	251.0	245.5	0.1%
Ratio to Revenue	22.9%	19.6%			18.9%	19.6%	19.5%	
Income tax expense	18.0	9.8	-8.2	-45.4%	49.9			
Profit	58.5	50.4	-8.1	-13.9%	195.4	202.0	197.5	1.1%
Ratio to Revenue	17.5%	16.4%			15.0%	15.8%	15.7%	
Comprehensive income	27.0	55.4	28.4	104.9%	156.7			

2. Consolidated Results (Core Basis)

Unit: B¥

	FY19 APR. - JUN.	FY20 APR. - JUN.	Change	Change (%)	FY19 Full Year	Initial Forecasts FY20 Full Year	Revised Forecasts FY20 Full Year	Change from FY19 FY20 (%)
Revenue	334.1	307.0	-27.2	-8.1%	1,300.8	1,282.0	1,256.5	-3.4%
Cost of sales	70.5	59.7	-10.9	-15.4%	276.7			
Ratio to Revenue	21.1%	19.4%			21.3%			
Gross profit	263.6	247.3	-16.3	-6.2%	1,024.1			
SG&A expenses	117.5	120.8	3.3	2.8%	499.3			
Ratio to Revenue	35.2%	39.3%			38.4%			
Advertising and Sales Promotion	41.3	42.0	0.7	1.8%	172.4			
Personnel expenses	43.6	45.7	2.1	4.8%	179.8			
Other	32.6	33.1	0.5	1.5%	147.0			
R&D expenses	53.5	57.3	3.8	7.1%	224.2	239.0	233.5	4.1%
Ratio to Revenue	16.0%	18.7%			17.2%	18.6%	18.6%	
Amortisation of intangible assets	7.2	5.9	-1.3	-18.4%	21.2			
Share of profit (loss) of investments accounted for using equity method	-0.7	-0.0	0.7	-	-1.7			
Operating profit	84.7	63.4	-21.4	-25.2%	277.8	257.0	251.0	-9.6%
Ratio to Revenue	25.4%	20.6%			21.4%	20.0%	20.0%	
Finance income	0.8	0.4	-0.4	-50.5%	4.4			
Finance expenses	1.3	1.0	-0.4	-27.8%	3.0			
Profit before tax	84.2	62.8	-21.4	-25.4%	279.1			
Ratio to Revenue	25.2%	20.5%			21.5%			
Income tax expense	17.1	10.8	-6.3	-36.7%	55.9			
Profit	67.1	52.0	-15.1	-22.5%	223.2	206.0	200.5	-10.2%
Ratio to Revenue	20.1%	16.9%			17.2%	16.1%	16.0%	

3. Exchange Rate

Unit: yen

	FY19 APR. - JUN.Ave.	FY20 APR. - JUN.Ave.	FY19 End	FY20 Q1 End	FY19 Full Year	Initial Forecasts FY20 Full Year	Revised Forecasts FY20 Full Year
USD/Yen	110	108	109	108	109	110	109
EUR/Yen	123	118	120	121	121	120	120

* Fx impacts: Revenue -7.1 billion yen and Core operating profit -5.8 billion yen

* Fx impact on elimination of unrealized gain: COGs ratio +1.1ppt

4. Reconciliation of Full Basis to Core Basis

Unit: B¥

	FY19 APR. - JUN.			FY20 APR. - JUN.		
	Full basis	Adjustment	Core basis	Full basis	Adjustment	Core basis
Revenue	**334.1**	**-**	**334.1**	**307.0**	**-**	**307.0**
Cost of sales	70.5	-	70.5	59.7	-	59.7
Gross profit	**263.6**	**-**	**263.6**	**247.3**	**-**	**247.3**
SG&A expenses	117.5	-	117.5	120.8	-	120.8
R&D expenses	53.5	-	53.5	57.3	-	57.3
Amortisation of intangible assets	7.2	-	7.2	5.9	-	5.9
Share of profit (loss) of investments accounted for using equity method	-0.7	-	-0.7	-0.0	-	-0.0
Other income *	4.5	-4.5	-	2.2	-2.2	-
Other expenses *	12.2	-12.2	-	4.8	-4.8	-
Operating profit	**77.1**	**7.7**	**84.7**	**60.8**	**2.6**	**63.4**
Finance income	0.8	-	0.8	0.4	-	0.4
Finance expenses	1.3	-	1.3	1.0	-	1.0
Profit before tax	**76.5**	**7.7**	**84.2**	**60.2**	**2.6**	**62.8**
Income tax expense	18.0	-0.9	17.1	9.8	1.0	10.8
Profit	**58.5**	**8.6**	**67.1**	**50.4**	**1.6**	**52.0**

* "Other income" and "Other expenses" are excluded from Full basis results.
"Other income" and "Other expenses" include gain/loss on sale and disposal of property, plant and equipment, impairment losses, restructuring costs, litigation costs and foreign exchange gains/losses, etc.

5. Revenue by Region

Unit: B¥

		FY19 APR. - JUN.	FY20 APR. - JUN.	Change	Change (%)	FY19 Full Year	FY20 Full Year Initial Forecasts	FY20 Full Year Revised Forecasts	Change from FY19 (%)
Revenue		334.1	307.0	-27.2	-8.1%	1,300.8	1,282.0	1,256.5	-3.4%
	Japan	98.5	77.8	-20.7	-21.0%	345.4	289.1	281.7	-18.4%
	Ratio to Revenue	29.5%	25.3%			26.6%	22.6%	22.4%	
	United States	105.3	117.2	11.9	11.3%	443.5	490.9	486.4	9.7%
	Ratio to Revenue	31.5%	38.2%			34.1%	38.3%	38.7%	
	Established Market	75.8	64.0	-11.7	-15.5%	296.1	299.0	287.5	-2.9%
	Ratio to Revenue	22.7%	20.9%			22.8%	23.3%	22.9%	
	Greater China	14.7	14.2	-0.5	-3.4%	60.4	67.6	67.2	11.4%
	Ratio to Revenue	4.4%	4.6%			4.6%	5.3%	5.4%	
	International	34.2	30.2	-4.0	-11.8%	134.8	120.1	117.1	-13.1%
	Ratio to Revenue	10.2%	9.8%			10.4%	9.4%	9.3%	
	Others	5.6	3.6	-2.0	-36.4%	20.7	15.3	16.5	-20.5%
	Ratio to Revenue	1.7%	1.2%			1.6%	1.2%	1.3%	

- Established Market: Europe, Canada, Australia
- Greater China: China, Hong Kong, Taiwan
- International: Russia, Latin America, Middle East, Africa, South East Asia, South Asia, Korea, Export sales, etc.

6. Addition to Property, Plant and Equipment
Depreciation/Amortisation

Unit: B¥

		FY19 APR. - JUN.	FY20 APR. - JUN.	Change	Change (%)	FY19 Full Year	FY20 Full Year Initial Forecasts	FY20 Full Year Revised Forecasts	Change from FY19 (%)
Addition to Property, Plant and Equipment									
	Consolidated	12.6	7.1	-5.5	-43.8%	41.8	29.0	29.0	-30.6%
Depreciation (PP&E)									
	Consolidated	8.0	10.0	2.0	24.5%	37.5	41.0	41.0	9.3%
Amortisation of Intangible Assets (incl. software, etc.)									
	Consolidated	9.0	8.0	-1.0	-10.9%	28.9	30.0	30.0	3.9%

- Addition to Property, Plant and Equipment does not include right-of-use asset.

7. Sales of major products

1) Global

Unit: B¥

	FY19 APR. - JUN.	FY20 APR. - JUN.	Change	Change (%)
XTANDI	96.0	112.0	16.0	16.6%
United States	46.9	62.7	15.8	33.7%
ex-US	49.1	49.3	0.2	0.3%
Japan	9.3	10.1	0.8	9.1%
Established Market	33.6	31.5	-2.1	-6.4%
Greater China	0.5	0.7	0.2	31.4%
International	5.7	6.9	1.3	22.7%
XOSPATA	2.5	5.6	3.2	128.3%
Japan	0.6	1.0	0.4	70.3%
United States	1.9	3.6	1.7	92.3%
Estabilished Market	-	1.0	1.0	-
PADCEV	-	3.0	3.0	-
United States	-	3.0	3.0	-
Betanis/Myrabetriq/BETMIGA	39.9	40.4	0.5	1.2%
Japan	9.4	8.4	-1.0	-10.5%
United States	21.3	22.9	1.6	7.7%
Estabilished Market	6.8	6.6	-0.2	-2.3%
Greater China	0.4	0.4	0.0	12.3%
International	2.1	2.0	-0.1	-2.5%
Vesicare	13.6	7.7	-5.8	-43.0%
Japan	5.7	4.9	-0.8	-13.8%
United States	0.2	0.4	0.2	85.7%
Estabilished Market	6.1	1.3	-4.8	-79.2%
Greater China	0.5	0.2	-0.3	-52.9%
International	1.1	0.9	-0.2	-14.3%
Prograf	50.4	45.3	-5.1	-10.2%
Japan	12.2	11.1	-1.1	-9.1%
United States	3.2	3.6	0.3	10.1%
Estabilished Market	17.7	13.8	-3.9	-21.9%
Greater China	7.7	7.8	0.1	1.3%
International	9.6	9.0	-0.6	-6.0%
Harnal/Omnic	10.9	10.6	-0.3	-3.1%
Funguard/MYCAMINE	9.0	7.1	-1.9	-21.6%
Eligard	3.6	3.1	-0.6	-16.0%

Unit: B¥

	FY19 Full Year	Initial Forecasts FY20 Full Year	Revised Forecasts FY20 Full Year	Change from FY19 Change (%)
XTANDI	400.0	459.3	464.6	16.1%
United States	203.5	238.3	249.5	22.6%
ex-US	196.5	221.0	215.1	9.5%
Japan	35.8	39.3	38.9	8.8%
Established Market	135.4	148.3	142.9	5.5%
Greater China	3.2	6.9	6.9	115.0%
International	22.1	26.5	26.4	19.5%
XOSPATA	14.3	23.2	23.1	61.9%
Japan	2.8	3.2	3.2	16.3%
United States	10.5	13.8	13.8	30.8%
Estabilished Market	0.9	5.6	5.5	486.2%
PADCEV	1.8		13.0	619.6%
United States	1.8		13.0	619.6%
Betanis/Myrabetriq/BETMIGA	161.6	172.5	167.9	3.9%
Japan	34.3	34.9	34.2	-0.5%
United States	89.2	93.0	90.8	1.7%
Estabilished Market	28.2	31.4	30.5	8.4%
Greater China	1.4	3.1	3.1	125.0%
International	8.4	10.1	9.3	10.6%
Vesicare	44.7	32.4	30.0	-32.9%
Japan	20.2	17.2	17.1	-15.4%
United States	5.4	3.1	2.2	-59.0%
Estabilished Market	13.1	6.5	5.2	-60.3%
Greater China	1.8	1.2	1.2	-34.7%
International	4.2	4.5	4.3	3.1%
Prograf	192.9	186.3	182.0	-5.7%
Japan	44.3	41.1	40.5	-8.7%
United States	13.2	12.2	12.1	-8.2%
Estabilished Market	71.5	65.3	62.6	-12.4%
Greater China	32.2	35.4	35.1	9.2%
International	31.7	32.4	31.6	-0.4%
Harnal/Omnic	42.7	40.5	39.1	-8.3%
Funguard/MYCAMINE	35.2	25.1	23.1	-34.4%
Eligard	14.2	12.9	12.3	-13.3%

- Sales of products in Japan are shown in a gross sales basis
- EM(Established Market): Europe, Canada, Australia
- Greater China: China, Hong Kong, Taiwan
- International: Russia, Latin America, Middle East, Africa, South East Asia, South Asia, Korea, Export sales, etc.

2）Revenue by region

(1) Japan

Unit: B¥

<Global>	FY19 APR. - JUN.	FY20 APR. - JUN.	Change	Change (%)	FY19 Full Year	FY20 Initial Forecasts Full Year	FY20 Revised Forecasts Full Year	Change from FY19 (%)
XTANDI	9.3	10.1	0.8	9.1%	35.8	39.3	38.9	8.8%
XOSPATA	0.6	1.0	0.4	70.3%	2.8	3.2	3.2	16.3%
Betanis	9.4	8.4	-1.0	-10.5%	34.3	34.9	34.2	-0.5%
Vesicare	5.7	4.9	-0.8	-13.8%	20.2	17.2	17.1	-15.4%
Prograf （Including Graceptor）	12.2	11.1	-1.1	-9.1%	44.3	41.1	40.5	-8.7%
Harnal	1.2	0.8	-0.4	-30.5%	4.1	2.6	2.6	-36.2%
Funguard	2.0	1.5	-0.5	-24.5%	7.6	3.6	3.6	-53.0%
<Main products>								
Suglat [Family]	6.0	7.1	1.1	18.3%	23.9	32.3	30.3	26.7%
Sujanu	2.1	2.8	0.7	34.9%	8.9			
Repatha	0.8	1.2	0.4	52.5%	3.1			
Linzess	1.4	1.6	0.2	12.3%	5.6	6.6	6.6	19.4%
BLINCYTO	1.0	1.2	0.1	12.0%	4.5			
EVENITY	3.5	6.9	3.4	96.1%	23.6			
Celecox	13.1	11.6	-1.6	-11.9%	49.2	20.9	20.9	-57.4%
Symbicort	11.0	-	-11.0	-	14.1			
Geninax	2.2	0.6	-1.6	-72.6%	7.7	7.1	5.0	-35.6%
Vaccines	3.3	0.0	-3.3	-99.9%	11.2	7.4	7.4	-34.0%
Gonax	1.3	1.6	0.3	23.2%	5.1	5.5	5.5	8.0%
Cimzia	2.4	2.5	0.1	4.4%	9.3	9.4	9.4	1.6%
Micardis [Family]	5.3	-	-5.3	-	17.7			
Bonoteo	1.8	1.1	-0.7	-40.4%	6.0	3.2	3.2	-46.3%
Lipitor	3.7	2.9	-0.8	-21.2%	12.7	10.0	10.2	-19.3%
Myslee	2.5	2.1	-0.4	-17.3%	9.0	7.2	7.2	-20.3%
Total Rx Sales In Japanese market	97.9	76.9	-21.0	-21.5%	342.1	283.0	275.6	-19.5%

- Sales of products in Japan are shown in a gross sales basis.

(2) United States

Unit: M$

	FY19 APR. - JUN.	FY20 APR. - JUN.	Change	Change (%)	FY19 Full Year	Initial Forecasts FY20 Full Year	Revised Forecasts FY20 Full Year	Change from FY19 FY20 Full Year Change (%)
Revenue	958	1,089	131	13.6%	4,078	4,463	4,446	9.0%
XTANDI	427	583	156	36.5%	1,871	2,166	2,280	21.8%
XOSPATA	17	33	16	96.4%	97	125	126	30.0%
PADCEV	-	27	27	-	17		119	615.2%
Myrbetriq	194	213	19	10.0%	821	845	830	1.1%
VESIcare	2	4	2	89.6%	50	28	20	-59.3%
Prograf	29	33	4	12.4%	122	111	111	-8.7%
MYCAMINE	26	24	-3	-10.5%	106	78	62	-41.8%
AmBisome	27	22	-4	-16.3%	116	118	106	-8.7%
CRESEMBA	37	36	-1	-2.3%	155	167	155	0.0%
Scan	185	111	-74	-40.1%	694	708	626	-9.8%
Tarceva	15	3	-12	-82.4%	30			

(3) Established Market

Unit: M€

	FY19 APR. - JUN.	FY20 APR. - JUN.	Change	Change (%)	FY19 Full Year	FY20 Full Year	FY20 Full Year	Change (%)
Revenue	613	540	-73	-11.9%	2,451	2,492	2,403	-1.9%
XTANDI	272	266	-7	-2.4%	1,121	1,236	1,195	6.6%
XOSPATA	-	9	9	-	8	47	46	492.1%
BETMIGA	55	56	1	1.8%	233	262	255	9.4%
Vesicare	49	11	-39	-78.4%	108	54	43	-59.9%
Prograf	143	117	-27	-18.5%	592	544	524	-11.5%
Omnic	17	15	-2	-11.8%	71	68	63	-11.1%
MYCAMINE	15	13	-1	-10.0%	56	40	40	-27.9%
Eligard	25	21	-3	-13.3%	98	85	81	-17.1%

- Established Market: Europe, Canada, Australia

(4) Greater China

Unit: B¥

	FY19 APR. - JUN.	FY20 APR. - JUN.	Change	Change (%)	FY19 Full Year	Initial Forecasts FY20 Full Year	Revised Forecasts FY20 Full Year	Change from FY19 (%)
Revenue	14.7	14.2	-0.5	-3.4%	60.4	67.6	67.2	11.4%
XTANDI	0.5	0.7	0.2	31.4%	3.2	6.9	6.9	115.0%
BETMIGA	0.4	0.4	0.0	12.3%	1.4	3.1	3.1	125.0%
Vesicare	0.5	0.2	-0.3	-52.9%	1.8	1.2	1.2	-34.7%
Prograf	7.7	7.8	0.1	1.3%	32.2	35.4	35.1	9.2%
Harnal	3.3	3.7	0.4	12.6%	13.1	11.4	11.4	-13.1%
MYCAMINE	0.9	0.5	-0.4	-45.6%	3.8	3.7	3.7	-2.4%
Eligard	0.1	0.1	0.0	16.8%	0.3	0.4	0.4	19.3%
Feburic	0.6	0.6	-0.0	-2.6%	2.5	4.0	3.9	56.0%

- Greater China: China, Hong Kong, Taiwan

(5) International

Unit: B¥

	FY19 APR. - JUN.	FY20 APR. - JUN.	Change	Change (%)	FY19 Full Year	Initial Forecasts FY20 Full Year	Revised Forecasts FY20 Full Year	Change from FY19 (%)
Revenue	34.2	30.2	-4.0	-11.8%	134.8	120.1	117.1	-13.1%
XTANDI	5.7	6.9	1.3	22.7%	22.1	26.5	26.4	19.5%
BETMIGA	2.1	2.0	-0.1	-2.5%	8.4	10.1	9.3	10.6%
Vesicare	1.1	0.9	-0.2	-14.3%	4.2	4.5	4.3	3.1%
Prograf	9.6	9.0	-0.6	-6.0%	31.7	32.4	31.6	-0.4%
Harnal	4.3	4.2	-0.1	-1.4%	16.9	18.2	17.6	4.1%
MYCAMINE	1.4	1.0	-0.4	-31.2%	5.5	4.4	4.2	-23.2%

- International: Russia, Latin America, Middle East, Africa, South East Asia, South Asia, Korea, Export sales, etc.

8. Consolidated statements of financial position

Unit: B¥

	FY19 End	FY20 Q1 End	Change
Assets	**2,315.2**	**2,256.0**	**-59.1**
Non-current assets	**1,447.7**	**1,460.1**	**12.4**
Property, plant and equipment	268.6	267.1	-1.5
Goodwill	278.3	276.9	-1.4
Intangible assets	724.8	729.4	4.6
Trade and other receivables	34.0	34.0	0.0
Investments accounted for using equity method	4.7	4.9	0.2
Deferred tax assets	52.9	55.5	2.6
Other financial assets	74.3	82.0	7.7
Other non-current assets	10.2	10.3	0.1
Current assets	**867.5**	**796.0**	**-71.5**
Inventories	151.0	155.1	4.1
Trade and other receivables	347.0	360.7	13.7
Income tax receivable	23.6	16.1	-7.5
Other financial assets	9.5	4.6	-4.9
Other current assets	18.0	19.6	1.5
Cash and cash equivalents	318.4	239.9	-78.5

Unit: B¥

	FY19 End	FY20 Q1 End	Change
Equity and Liabilities	**2,315.2**	**2,256.0**	**-59.1**
Equity	**1,289.2**	**1,306.7**	**17.5**
Equity attributable to owners of the parent	**1,289.2**	**1,306.7**	**17.5**
Share capital	103.0	103.0	-
Capital surplus	177.5	177.2	-0.3
Treasury shares	-7.2	-7.4	-0.2
Retained earnings	905.9	918.9	13.0
Other components of equity	110.0	115.0	5.0
Liabilities	**1,026.0**	**949.4**	**-76.7**
Non-current liabilities	**227.3**	**301.7**	**74.4**
Trade and other payables	3.1	2.8	-0.3
Deferred tax liabilities	24.7	20.8	-3.9
Retirement benefit liabilities	38.1	38.6	0.5
Provisions	6.1	7.6	1.5
Other financial liabilities	129.3	208.3	79.0
Other non-current liabilities	26.0	23.6	-2.4
Current liabilities	**798.7**	**647.7**	**-151.0**
Trade and other payables	172.0	132.6	-39.3
Income tax payable	4.0	12.1	8.1
Provisions	14.2	14.5	0.3
Other financial liabilities	345.7	235.7	-110.0
Other current liabilities	262.8	252.7	-10.1

In the first three months of FY2020, the consolidated statement of financial position as of March 31, 2020 was retroactively revised due to adjustments of fair value of assets acquired and liabilities assumed for Audentes Therapeutics, Inc., which was acquired in January 2020. For the details, refer to Note "Business Combinations" in Financial Results.

R&D Pipeline

The list shows the development status in the target diseases for which we aim to obtain approval in Japan, the United States, Europe and/or China. As of Aug 2020

Underlined items indicate changes from the previous announcement on May 2020.

Key post-POC projects and projects to maximize their VALUE (1/2)

Therapeutic Area	Generic Name Code No. (Brand Name)	Modality / Technology	Classification	Target Disease	Phase *	Licensor **	Remarks
Oncology	**enzalutamide MDV3100 (XTANDI®)**	Small molecule	Androgen receptor inhibitor	Non-metastatic castration-resistant prostate cancer	China Filed (Oct 2019)	Pfizer	
				Metastatic castration-sensitive prostate cancer	Japan Approved (May 2020) Europe Filed (Jul 2019) China P-III		
				Non-metastatic castration-sensitive prostate cancer	P-III		
	gilteritinib ASP2215 (XOSPATA®)	Small molecule	FLT3 inhibitor	Relapsed or refractory acute myeloid leukemia	China Filed (Mar 2020)	In-house	
				Post-chemotherapy maintenance acute myeloid leukemia	P-III		
				Post-hematopoietic stem cell transplant maintenance acute myeloid leukemia	P-III		
				Newly diagnosed acute myeloid leukemia with low intensity induction of chemotherapy	P-III		
				Newly diagnosed acute myeloid leukemia with high intensity induction of chemotherapy	P-III		
				Acute myeloid leukemia in pediatric patients	P-III		
	enfortumab vedotin ASG-22ME (PADCEV®)	Antibody-drug conjugate (ADC)	Nectin-4 targeted ADC	Metastatic urothelial cancer, PD-1/PD-L1 inhibitor and platinum-containing chemotherapy pretreated	P-III	In-house [Co-development with Seattle Genetics]	
				Metastatic urothelial cancer, previously untreated (first line; combo with pembrolizumab)	P-III		
				Metastatic urothelial cancer, PD-1/PD-L1 inhibitor pretreated	P-II		
				Other solid tumors	P-II		
	zolbetuximab IMAB362	Antibody	Anti-Claudin 18.2 monoclonal antibody	Gastric and gastroesophageal junction adenocarcinoma	P-III	In-house (Ganymed)	
				Pancreatic adenocarcinoma	P-II		

Key post-POC projects and projects to maximize their VALUE (2/2)

Therapeutic Area	Generic Name Code No. (Brand Name)	Modality / Technology	Classification	Target Disease	Phase *	Licensor **	Remarks
Urology and Nephrology	**roxadustat ASP1517/FG-4592**	Small molecule	HIF-PH inhibitor	Anemia associated with chronic kidney disease in patients on dialysis	Europe Filed (Apr 2020)	FibroGen	Astellas has rights in Japan, Europe, the Commonwealth of Independent States, the Middle East, and South Africa.
				Anemia associated with chronic kidney disease in patients not on dialysis	Japan Filed (Jan 2020) Europe Filed (Apr 2020)		
				Chemotherapy-induced anemia	P-II		
Others	**fezolinetant ESN364**	Small molecule	NK3 receptor antagonist	Menopause-related vasomotor symptoms	P-III	In-house (Ogeda)	

* Compounds are developed globally unless noted. The list shows the most advanced stage if the stages are different depending on the region. The list specifies the area if the compound is developed in limited areas.
** Compounds with "In-house" in this column include ones discovered by collaborative research.

Updates from the previous announcement (May 2020):
enzalutamide (MDV3100): Approved in Japan for prostate cancer with distant metastasis in May 2020.
roxadustat (ASP1517/FG-4592): Filed in Europe for anemia in adult patients with chronic kidney disease in Apr 2020.
gilteritinib (ASP2215): Initiated a new Phase 3 study for acute myeloid leukemia in pediatric patients.

Projects with Focus Area approach (1/2)

Target (Biology)	Generic Name Code No. (Brand Name)	Modality / Technology	Therapeutic Area	Classification	Target Disease	Phase *	Licensor **	Remarks
Immuno-oncology	**ASP8374/PTZ-201**	Antibody	Oncology	Anti-TIGIT antibody	Cancer	P-I	In-house (Potenza Therapeutics)	
	ASP1948/PTZ-329	Antibody	Oncology	Anti-NRP1 antibody	Cancer	P-I	In-house (Potenza Therapeutics)	
	ASP1951/PTZ-522	Antibody	Oncology	GITR agonistic antibody	Cancer	P-I	In-house (Potenza Therapeutics)	
	ASP9801	Oncolytic virus	Oncology	Oncolytic virus carrying IL-7 and IL-12	Cancer	P-I	Tottori University [Discovered through collaborative research]	
	ASP7517	Cell therapy (artificial adjuvant vector cells)	Oncology	WT1 loaded artificial adjuvant vector cell	Cancer	P-I	RIKEN [Discovered through collaborative research]	
Regeneration	**ASP7317**	Cell therapy	Ophthalmology	Retinal pigment epithelium cells	Dry age-related macular degeneration, Stargardt disease	P-II	In-house (Astellas Institute for Regenerative Medicine)	
	FX-322	Small molecule	Otology	Inner ear progenitor cell activator (combination of GSK-3 inhibitor and HDAC inhibitor)	Sensorineural hearing loss	P-II	Frequency Therapeutics	Astellas has rights in Ex-US markets
	ASP0598	Recombinant protein	Otology	Recombinant human heparin-binding epidermal growth factor-like growth factor	Chronic tympanic membrane perforation	P-I	Auration Biotech	
Antigen-specific immuno-modulation (ASIM)	**ASP0892**	Next generation vaccine (LAMP-vax technology)	Immunology		Peanut allergy	P-I	Immunomic Therapeutics	
	ASP2390	New generation vaccine (LAMP-vax technology)	Immunology		House dust mite-induced allergic rhinitis	P-I	Immunomic Therapeutics [Discovered through collaborative research]	

Projects with Focus Area approach (2/2)

Target (Biology)	Generic Name Code No. (Brand Name)	Modality / Technology	Therapeutic Area	Classification	Target Disease	Phase *	Licensor **	Remarks
Mitochondria	**ASP1128/MA-0217**	Small molecule	Nephrology	PPARδ modulator	Acute kidney injury	P-II	In-house (Mitobridge)	
	ASP0367/MA-0211	Small molecule	Muscle disease		Duchenne muscular dystrophy	P-I	In-house (Mitobridge)	
Genetic regulation	**resamirigene bilparvovec AT132**	Gene therapy (AAV-based gene therapy)	Muscle disease	MTM1 gene replacement to express myotubularin	X-linked myotubular myopathy	P-II	In-house (Audentes)	
	AT845	Gene therapy (AAV-based gene therapy)	Muscle disease	GAA gene replacement to express GAA enzyme	Pompe disease	P-I	In-house (Audentes)	
Others	**ASP3772**	Next generation vaccine (MAPS technology)	Infectious disease	Pneumococcal vaccine based on a multiple antigen-presenting system (MAPS) platform	Prevention of pneumococcal disease	P-II	Affinivax	

* Compounds are developed globally unless noted. The list shows the most advanced stage if the stages are different depending on the region. The list specifies the area if the compound is developed in limited areas.
** Compounds with "In-house" in this column include ones discovered by collaborative research.

Others

Therapeutic Area	Generic Name Code No. (Brand Name)	Modality / Technology	Classification	Target Disease	Phase *	Licensor **	Remarks
Oncology	**ASP1650**	Antibody	Anti-Claudin 6 monoclonal antibody	Testicular cancer	P-II	In-house (Ganymed)	
	ASP1235/AGS62P1	Antibody-drug conjugate (ADC)		Acute myeloid leukemia	P-I	In-house [ADC technology, EuCODE license from Ambrx]	
Urology and Nephrology	**solifenacin YM905 (VESIcare LS)**	Small molecule	Muscarine M_3 receptor antagonist	Neurogenic detrusor overactivity in pediatric patients	US Approved (May 2020)	In-house	
	mirabegron YM178	Small molecule	β_3 receptor agonist	Overactive bladder and neurogenic detrusor overactivity in pediatric patients	P-III	In-house	
	ASP8302	Small molecule	Muscarine M_3 receptor positive allosteric modulator	Underactive bladder	P-II	In-house	
Immunology	**peficitinib ASP015K**	Small molecule	JAK inhibitor	Rheumatoid arthritis	China P-III	In-house	
	bleselumab ASKP1240	Antibody	Anti-CD40 monoclonal antibody	Recurrence of focal segmental glomerulosclerosis in de novo kidney transplant recipients	P-II	Kyowa Kirin	
	ASP1617	Small molecule		Systemic lupus erythematosus	P-I	In-house	
Others	**isavuconazole**	Small molecule	Azole antifungal	Invasive aspergillosis and mucormycosis in pediatric patients	US P-II	Basilea	
	ASP8062	Small molecule	$GABA_B$ receptor positive allosteric modulator	Substance use disorders	P-I	In-house	

* Compounds are developed globally unless noted. The list shows the most advanced stage if the stages are different depending on the region. The list specifies the area if the compound is developed in limited areas.
** Compounds with "In-house" in this column include ones discovered by collaborative research.

Update from the previous announcement (May 2020):
fidaxomicin: Removed the description of the approval in Europe for *clostridium difficile* infection in pediatric patients in Feb 2020.
solifenacin (YM905): Approved in US for neurogenic detrusor overactivity in pediatric patients aged 2 years and older in May 2020.

Rx+ Program

As of August 2020

Underlined item indicates changes from the previous announcement on May 2020

Sphere (Business area)	Project	Concept	Status	Partner	Remarks
Chronic disease progression prevention	Smartphone application	Offer smartphone application to support exercise using wearable device to people who needs regular exercise	Implementing medical and health research	BANDAI NAMCO Entertainment	
	Fitness service (Fit-eNce)	Scientifically evidenced exercise programs and systems which support regular exercise	Preparing to begin sales through fitness clubs in limited regions		
	BlueStar	Digital therapeutics for adults with diabetes	Under development	Welldoc, Inc.	
Patient outcome maximization	ASP5354	Precision surgery-guide enabling identification of ureter in hysterectomy and colorectal surgery etc.	P-Ⅱ		

Update from the previous announcement (May 2020):
Fitness service (Fit-eNce) : Added as a new project